Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

BioForm Medical Receives FDA Approval for Mixing Lidocaine With RADIESSE(r) Dermal Filler

Thu. July 16, 2009; Posted: 08:00 AM
Stocks RSS
SAN MATEO, Calif., Jul 16, 2009 (GlobeNewswire via COMTEX) -- BFRM | Quote | Chart | News | PowerRating -- BioForm Medical, Inc. (Nasdaq:BFRM) today announced U.S. Food and Drug Administration (FDA) approval for a method of mixing RADIESSE(r) dermal filler with lidocaine, which, in clinical trials, has demonstrated an improvement in patient comfort and an increase in patient satisfaction with RADIESSE dermal filler procedures. BioForm Medical will immediately begin commercial efforts to educate physicians to use this method of mixing RADIESSE dermal filler with lidocaine.

"Dermal filler procedures can create some level of patient discomfort due to injection pain. Being able to mix RADIESSE dermal filler with lidocaine has been proven to provide a significant advantage in improving patient comfort," stated Rhoda S. Narins, M.D., former President of the American Society for Dermatologic Surgery (ASDS) and a Clinical Professor of Dermatology at NYU Medical Center. "I have found in my practice that mixing with lidocaine makes RADIESSE dermal filler easier to use in many treatment areas."

This technique for mixing RADIESSE with lidocaine was developed by Mariano Busso, M.D. and the methodology was first published in the Journal of Dermatologic Surgery in June 2008. BioForm Medical conducted a 50-patient controlled clinical trial to evaluate the safety and effectiveness of mixing RADIESSE dermal filler with lidocaine. Patients in the split-face trial at two clinical sites reported that RADIESSE dermal filler mixed with 2% lidocaine was less painful than RADIESSE dermal filler not mixed with lidocaine, while providing comparable aesthetic correction. The results from the clinical trial demonstrated:



 * Approximately 60% reduction in scores immediately following
   treatment, measured on a Visual Analog Scale for Pain (VAS)
   (p<0.0001).
 * 100% of patients found RADIESSE dermal filler mixed with lidocaine
   to be less painful than non-mixed RADIESSE dermal filler.
 * 96% of patients found that the difference was significant enough
   to affect their preference for one treatment over the other.
 * Both RADIESSE dermal filler mixed with lidocaine and non-mixed
   RADIESSE dermal filler were safe, with comparable local adverse
   events, typical of dermal fillers. There were no serious adverse
   events in the clinical trial.
 * RADIESSE dermal filler mixed with lidocaine produced a comparable
   aesthetic improvement as compared with treatment with RADIESSE
   dermal filler without premixing.

The clinical study which supported this approval by FDA was conducted by Ellen S. Marmur, M.D., Chief of Dermatologic and Cosmetic Surgery, Mount Sinai Medical Center in New York, N.Y., and Lawrence J. Green, M.D., Assistant Clinical Professor of Dermatology, George Washington University School of Medicine in Washington, D.C.

The method approved by FDA is based on using a mixing syringe and the female-to-female luer lock connector to mix RADIESSE dermal filler and lidocaine. Components for this mixing technique are commercially available through various sources, however, in the near future, BioForm Medical will be providing them in an separate Accessory Kit as a further convenience to its customers.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is RADIESSE(r) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. For more information about BioForm Medical, please visit www.bioform.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: BioForm Medical, Inc.

BioForm Medical, Inc.
          Can Gumus, Senior Manager, Corporate Development
          650.286.4003
For full details for BFRM click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [BFRM]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.